Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
Key Highlights
- ➤Aurora (ACB) unanimously recommends shareholders reject Curaleaf’s (CURA; CURLF) revised hostile bid
- ➤Updated fairness opinion finds Curaleaf’s revised consideration financially inadequate for Aurora shareholders
- ➤Aurora’s Special Committee is actively exploring alternatives, including third-party transactions or remaining independent
- ➤Aurora has confidentiality and standstill agreements with multiple parties examining company information
- ➤Curaleaf’s revised hostile bid remains open until December 4, 2026
Expert Statements
Miguel Martin, Executive Chairman and CEO of Aurora Cannabis
“Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today. Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount. At the same time, our Special Committee is carefully evaluating strategic alternatives with the goal of delivering greater value for Aurora shareholders. Curaleaf's offer remains open until December 4, 2026, so we believe shareholders gain nothing by tendering now, and tendering early could undermine the opportunity for a superior outcome. We urge shareholders to keep their options open, reject the revised Hostile Bid and take no action until they can consider all the alternatives available to them”
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside PR Newswire
* Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board. * Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders. * Shareholders are advised to REJECT the revised Hostile Bid and TAKE NO ACTION at this time before other strategic alternatives may emerge. * Questions about the Hostile Bid or would like to stay informed? Contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or email contactus@kingsdaleadvisors.com (mailto:contactus@kingsdaleadvisors.com) . EDMONTON, AB, Oct. 14, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global medical cannabis company, today reconfirms that the Board of Directors (the "Board"), on the unanimous recommendation of a special committee of independent directors (the "Special Committee"), unanimously recommends that shareholders REJECT the hostile offer by Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF) for all of the issued and outstanding common shares of the Company, as revised in the Notice of Variation, Change and Extension filed by Curaleaf on October 6, 2026 (the "Hostile Bid").
Get started
Create a free account to read the full story.